Compile Data Set for Download or QSAR
Report error Found 118 Enz. Inhib. hit(s) with all data for entry = 8252
TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238314(US9394273, 4 | US9394273, 3)
Affinity DataEC50: >1.00E+4nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238314(US9394273, 4 | US9394273, 3)
Affinity DataEC50: >1.00E+4nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238316(US9394273, 6 | US9394273, 5)
Affinity DataEC50:  78nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238316(US9394273, 6 | US9394273, 5)
Affinity DataEC50:  10nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238318(US9394273, 7)
Affinity DataEC50:  123nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  8nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  278nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  26nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238322(US9394273, 12 | US9394273, 11)
Affinity DataEC50:  1.01E+3nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238322(US9394273, 12 | US9394273, 11)
Affinity DataEC50:  35nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238330(US9394273, 20 | US9394273, 19)
Affinity DataEC50:  11nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238332(US9394273, 22 | US9394273, 21)
Affinity DataEC50:  76nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238332(US9394273, 22 | US9394273, 21)
Affinity DataEC50:  8nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238334(US9394273, 24 | US9394273, 23)
Affinity DataEC50:  30nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238336(US9394273, 26 | US9394273, 25)
Affinity DataEC50:  164nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238336(US9394273, 26 | US9394273, 25)
Affinity DataEC50:  8nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238338(US9394273, 28 | US9394273, 27)
Affinity DataEC50:  125nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP2 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238338(US9394273, 28 | US9394273, 27)
Affinity DataEC50:  10nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238312(US9394273, 2 | US9394273, 1)
Affinity DataEC50:  1nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238312(US9394273, 2 | US9394273, 1)
Affinity DataEC50:  21nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238314(US9394273, 4 | US9394273, 3)
Affinity DataEC50:  1.28E+3nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238314(US9394273, 4 | US9394273, 3)
Affinity DataEC50:  186nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238316(US9394273, 6 | US9394273, 5)
Affinity DataEC50:  1nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238316(US9394273, 6 | US9394273, 5)
Affinity DataEC50:  0.0400nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238318(US9394273, 7)
Affinity DataEC50:  2nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  0.0500nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  12nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238322(US9394273, 12 | US9394273, 11)
Affinity DataEC50:  16nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238322(US9394273, 12 | US9394273, 11)
Affinity DataEC50:  0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238324(US9394273, 14 | US9394273, 13)
Affinity DataEC50:  142nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238324(US9394273, 14 | US9394273, 13)
Affinity DataEC50:  8nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238326(US9394273, 15)
Affinity DataEC50:  0.5nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238327(US9394273, 16)
Affinity DataEC50:  728nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238329(US9394273, 18)
Affinity DataEC50:  2nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238330(US9394273, 20 | US9394273, 19)
Affinity DataEC50:  38nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238330(US9394273, 20 | US9394273, 19)
Affinity DataEC50:  0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238332(US9394273, 22 | US9394273, 21)
Affinity DataEC50:  4nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238332(US9394273, 22 | US9394273, 21)
Affinity DataEC50:  0.300nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238334(US9394273, 24 | US9394273, 23)
Affinity DataEC50:  21nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238334(US9394273, 24 | US9394273, 23)
Affinity DataEC50:  0.300nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238336(US9394273, 26 | US9394273, 25)
Affinity DataEC50:  30nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238336(US9394273, 26 | US9394273, 25)
Affinity DataEC50:  0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238338(US9394273, 28 | US9394273, 27)
Affinity DataEC50:  18nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238338(US9394273, 28 | US9394273, 27)
Affinity DataEC50:  0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP3 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238316(US9394273, 6 | US9394273, 5)
Affinity DataEC50:  3.72E+3nMpH: 7.4Assay Description:Calciium Signal Studies of the Flipr. Cells were seeded at a density of 5×104 cells per well in Biocoati Poly-D-lysine-coated black-wall, clear-botto...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP3 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  177nMpH: 7.4Assay Description:Calciium Signal Studies of the Flipr. Cells were seeded at a density of 5×104 cells per well in Biocoati Poly-D-lysine-coated black-wall, clear-botto...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP3 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 9 | US9394273, 8)
Affinity DataEC50:  180nMpH: 7.4Assay Description:Calciium Signal Studies of the Flipr. Cells were seeded at a density of 5×104 cells per well in Biocoati Poly-D-lysine-coated black-wall, clear-botto...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP3 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238326(US9394273, 15)
Affinity DataEC50:  67nMpH: 7.4Assay Description:Calciium Signal Studies of the Flipr. Cells were seeded at a density of 5×104 cells per well in Biocoati Poly-D-lysine-coated black-wall, clear-botto...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProstaglandin E2 receptor EP3 subtype(Human)
Allergan

US Patent
LigandPNGBDBM238330(US9394273, 20 | US9394273, 19)
Affinity DataEC50:  952nMpH: 7.4Assay Description:Calciium Signal Studies of the Flipr. Cells were seeded at a density of 5×104 cells per well in Biocoati Poly-D-lysine-coated black-wall, clear-botto...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 118 total ) | Next | Last >>
Jump to: